Fairvalue-Calculator Fairvalue-Calculator
EN DE

Xcell Therapeutics Inc (373110) Fair Value & Analysis

Healthcare · KR · Market cap 16.8B KRW

Price1,218 KRW
Fair Value1,724 KRW
Upside+41.5%
Quality95/100
Evidence: Low Range 1,293 KRW – 2,155 KRW

Fair value as of: Jun 24, 2026

Analysis

Xcell Therapeutics Inc (373110) currently trades at 1,218 KRW, while our model-based Fair Value estimate is 1,724 KRW — implying the stock looks roughly 41.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Xcell Therapeutics Inc (373110) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1,724 KRW versus a price of 1,218 KRW — about +42% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 373110?
Our 21-model fair value for Xcell Therapeutics Inc is 1,724 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 1,218 KRW.
What is the quality score of 373110?
Xcell Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.